Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors

Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors




Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #BoardofDirectors–Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Tiffany Olson has been appointed to its board of directors, effective immediately.

“We are pleased to welcome Tiffany to our board,” said Derek Maetzold, director, president and chief executive officer of Castle Biosciences. “Her leadership and experience as an executive in various public diagnostic companies provides her expertise in the operations of high-growth organizations like Castle and will bring valuable insight to the board.”

Tiffany Olson (age 61), since 2013, has served as president of Nuclear & Precision Health Solutions at Cardinal Health, which develops, manufactures, compounds, dispenses and delivers 12 million time-critical, patient specific doses annually to thousands of customers via a network of nuclear pharmacies and manufacturing sites that span the U.S. Prior to Cardinal Health, Olson was president of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Olson also worked for Roche Diagnostics, where she attained the position of president and chief executive officer of Roche Diagnostics Corporation. She was the first woman to receive the Life Science Alley Luminary Award, recognizing her “rich career in medical diagnostics…exceptional reputation as a leader and her vision to drive both innovation and value for personalized medicine.”

Olson was recognized as one of the 10 Best Women Leaders of 2020 by Industry Era. In 2013, she received the “Woman of Wellness Award” for her extraordinary contributions through her volunteer work in oncology. She currently serves as an ambassador with the American Cancer Society through the ResearcHERS: Women Fighting Cancer campaign, which helps fund women-led cancer research. She has written several articles on personalized medicine, molecular diagnostics and business strategy. Olson has a bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota. She has held several board positions, and currently serves as a board member of the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR).

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning the value Olson will add to Castle. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, whether Olson will add value to Castle and the risks set forth in our Annual Report on Form 10-Q for the quarter ended March 31, 2021, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

Contacts

Investor and Media Contact:
Camilla Zuckero

832-835-5158

czuckero@castlebiosciences.com